Literature DB >> 12548327

Desloratidine for the treatment of chronic urticaria.

E W Monroe1.   

Abstract

Chronic urticaria is a common dermatologic condition that is idiopathic in most cases. Antihistamines are the mainstays of treatment for this condition. The newer, second and third generation antihistamines are the preferred agents because of their improved safety profile and comparable efficacy to the first generation antihistamines. Desloratadine is a new non-sedating H1-receptor agonist. Based on clinical studies, desloratadine is a valuable new addition to the available treatment options and should be considered as a first-line therapy for patients with chronic urticaria.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12548327

Source DB:  PubMed          Journal:  Skin Therapy Lett        ISSN: 1201-5989


  5 in total

1.  The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy.

Authors:  Luis A Kluth; Shahrokh F Shariat; Christian Kratzik; Scott Tagawa; Guru Sonpavde; Malte Rieken; Douglas S Scherr; Karl Pummer
Journal:  World J Urol       Date:  2013-09-03       Impact factor: 4.226

2.  Acute cholestasis related to desloratidine.

Authors:  Ramon Pérez; Luis Rodrigo; Rosa Pérez; Ruth de Francisco
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

3.  Effects of Shenqi Fuzheng injection on Fas/FasL protein expression levels in the cardiomyocytes of a mouse model of viral myocarditis.

Authors:  Tianmin Wu; Jinshui Chen; Liufang Fan; Wenyan Xie; Changsheng Xu; Huajun Wang
Journal:  Exp Ther Med       Date:  2016-03-15       Impact factor: 2.447

Review 4.  Roles of histamine and its receptors in allergic and inflammatory bowel diseases.

Authors:  Hua Xie; Shao-Heng He
Journal:  World J Gastroenterol       Date:  2005-05-21       Impact factor: 5.742

Review 5.  Prodrugs for amines.

Authors:  Ana L Simplício; John M Clancy; John F Gilmer
Journal:  Molecules       Date:  2008-03-03       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.